| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
Estradiol propionate targets the estrogen receptor (ER). It enters target cells freely (e.g., female organs, breasts, hypothalamus, pituitary) and interacts with the ER. This interaction leads to the activation of estrogen-responsive genes, which regulate various physiological processes. It also acts as a progesterone agonist.
|
|---|---|
| ln Vitro |
In vitro, Estradiol propionate is used to study estrogen receptor-mediated signaling. It increases the amount of cGMP and, to a lesser extent, cAMP in the uterine tissues of ovariectomized rats. It induces a 3-fold increase in uterine glycogen content and a 4-fold decrease in vaginal glycogen content in mice.
|
| ln Vivo |
In vivo, Estradiol propionate is used in animal models to study the effects of estrogens. It is administered via subcutaneous injection. Its effects on the uterus, vagina, and other reproductive tissues are studied. It is not used as a therapeutic agent in humans.
|
| Enzyme Assay |
For in vitro receptor binding studies, the affinity of Estradiol propionate for the estrogen receptor can be assessed using radioligand binding assays. For functional studies, cells expressing the estrogen receptor are treated with the compound, and the expression of estrogen-responsive genes is measured.
|
| Cell Assay |
For in vitro cell-based assays, the activity of Estradiol propionate is evaluated using cell lines that express the estrogen receptor, such as MCF-7 breast cancer cells. Cells are treated with the compound, and cell proliferation, gene expression, and signaling pathways are studied.
|
| Animal Protocol |
For in vivo animal studies, Estradiol propionate is typically administered via subcutaneous injection in ovariectomized rodent models. Its effects on uterine weight, vaginal cytology, and other estrogen-responsive parameters are measured. Its pharmacokinetics and tissue distribution are also studied.
|
| ADME/Pharmacokinetics |
Estradiol propionate is administered parenterally. It is metabolized in the liver. Its pharmacokinetics are similar to other estradiol esters. It is a controlled substance and is used in research settings.
|
| Toxicity/Toxicokinetics |
Estradiol propionate can have significant hormonal effects. It is a potent estrogen and should be handled with caution. It is not intended for human use in research settings.
|
| References |
Lei, B., et al., beta-estradiol 17-valerate affects embryonic development and sexual differentiation in Japanese medaka (Oryzias latipes). Aquat Toxicol, 2013. 134-135: p. 128-34.
|
| Additional Infomation |
Estradiol propionate is a research compound used to study estrogen receptor signaling. It is not a clinically used drug. It is commercially available from chemical suppliers for research purposes only.
|
| Appearance |
Typically exists as solid at room temperature
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
